RECRUITING

ROSE-Longitudinal Assessment With Neuroimaging

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal would represent the largest, and longest advanced neuroimaging and RNA-sequencing evaluation after ICH to date.

Official Title

Recovery and Outcomes From Stroke-Longitudinal Assessment With Neuroimaging

Quick Facts

Study Start:2020-09-30
Study Completion:2025-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05089331

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or greater, fulfillment of the criteria for Deep, Subcortical or Lobar Intracerebral Hemorrhage
  2. * No evidence of trauma, vascular malformation or aneurysm, or brain tumor as a cause of ICH.
  3. * Ability of the patient or legal representative to provide informed consent
  1. * Brainstem or Cerebellar ICH
  2. * Patients Severely Affected by the ICH, Early Mortality, Hospice, or Withdraw of Care NOT eligible for ROS

Contacts and Locations

Study Contact

Lee A Gilkerson, RN, BSN
CONTACT
5139191822
Lee.gillkerson@uc.edu

Principal Investigator

Daniel Woo, MD, MS
PRINCIPAL_INVESTIGATOR
University of Cincinnati

Study Locations (Sites)

University of Illinois Chicago
Chicago, Illinois, 60612
United States
Baptist Health Louisville
Louisville, Kentucky, 40207
United States
University of Maryland
Baltimore, Maryland, 21201
United States
Columbia University
New York, New York, 10032
United States
Duke University
Durham, North Carolina, 27710
United States
University of Cincinnati
Cincinnati, Ohio, 45267
United States
Houston Methodist
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: University of Cincinnati

  • Daniel Woo, MD, MS, PRINCIPAL_INVESTIGATOR, University of Cincinnati

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-09-30
Study Completion Date2025-09-30

Study Record Updates

Study Start Date2020-09-30
Study Completion Date2025-09-30

Terms related to this study

Keywords Provided by Researchers

  • Hemorrhagic Stroke, Intracerebral
  • Intracerebral Hemorrhage
  • Outcomes after Stroke
  • Intracerebral hematoma

Additional Relevant MeSH Terms

  • Intracerebral Hemorrhage